RECURRENT PROSTATE CARCINOMA

This study tests whether adding an experimental drug (MK-2206) to standard hormone therapy (bicalutamide) works better than hormone therapy alone for men with prostate cancer whose PSA levels are rising after initial treatment. About 108 men will take part. The main goal is to se…

This study tests two types of radiation therapy—proton beam and IMRT—given in shorter courses for men whose prostate cancer has come back and spread only to pelvic or abdominal lymph nodes. The goal is to see if the shorter treatment is safer and causes fewer severe side effects.…

This study tests whether a white button mushroom supplement can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and being watched. About 133 men will take the supplement or be monitored as usual. The goal is to see if the mushroom aff…

This study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the hormone therapy enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while con…

This study tests whether combining surgery and radiation can help men whose prostate cancer has returned or spread to a few spots. About 20 participants will receive targeted radiation and/or surgical removal of those spots. The main goal is to see if this approach can significan…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in men with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combo can lower PSA lev…

This study looks at whether adding a drug called apalutamide to standard radiation therapy can better control prostate cancer that has come back after surgery. About 324 men with a rising PSA after prostate removal will receive either radiation plus apalutamide or radiation plus …

This study tests a combination of hormone therapy (leuprolide, apalutamide, abiraterone) and precise radiation (SBRT) in 28 men whose prostate cancer has returned and spread to a few spots. The goal is to see if this approach can lower PSA levels to nearly undetectable. Participa…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 participants will receive either hormone therapy alone or hormone thera…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests whether adding furosemide (a diuretic or "water pill") to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels rose after prostate removal. Participants receive two scans—one with and…

This study collects tissue, blood, and urine samples from 92 men with prostate cancer that has spread. Researchers look for gene changes that might explain how well the cancer responds to standard hormone therapy. The goal is to find biomarkers, not to test a new treatment.

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

This study looks at how certain hormone therapies for advanced prostate cancer affect men's thinking skills, like memory and concentration. Researchers will use brain scans and thinking tests to see if these treatments cause changes in the brain. The goal is to understand why som…